Triple Hair is a Canadian biotechnology company that is developing new topical treatments for men and women who suffer from androgenic alopecia. Its main hair loss product will enter Phase 3 trials in 2026 and contains Minoxidil (5%), Finasteride (0.1%) and Latanoprost (0.03%).
Triple Hair TH07 Phase 3 Clinical Trials Begin
Update: February 27, 2027
The Phase 3 trials for Triple Hair’s Therapy-07 (THO7) will start in Vancouver, British Columbia (Canada) in April 2026. They have started the process of recruiting 420 volunteers for this 24-week trial. Since all three of the key ingredients in TH07 are already FDA approved and well established, I would not be too concerned about side effects. But you should still consult a doctor first if you plan to enroll in this trial.
On the company’s website, they also state that they will conduct another Phase 3 trial in India.
June 20, 2024
Triple Hair: Therapy-07 for Hair Growth
Triple Hair’s main product is a prescription triple combination topical called Therapy-07. It contains minoxidil, finasteride and latanoprost (a prostaglandin F2α analog). It is currently sold via prescription through Texas-based Pharmacy Solutions.
When I first read about Therapy-07, while it seemed interesting, it did not sound like anything special to me. The reason is because there are now many online companies that sell topical finasteride containing hair loss products that also include minoxidil and other key ingredients such as latanoprost, spironolactone and resveratrol. In addition:
- A US-based company named Aneira Pharma is working a product that includes latanoprost, minoxidil and various other ingredients.
- Another US-based company Dermaliq is preparing for Phase clinical trials for its prostaglandin F2α analogue topical hair growth product DLQ01 that is thought to contain latanoprost.
- A Poland-based company BioReseach Pharma is working on a latanoprost acid based hair loss product.
Phase 3 Clinical Trial Approvals in Europe and Canada
However, today I changed my mind slightly after reader “John Doe” e-mailed me to notify that Triple Hair has just received EMA approval to start phase III clinical trials for its Therapy-07 prescription drug in Europe.
Do note that in June 2023, Triple Hair already received approval to begin phase III clinical trials in Canada. At the time, company CEO Jean-Philippe Gravel said that they were also awaiting similar approvals in the US and Europe. As soon as all approvals are obtained they planned to begin the final trials.
So far, among the many companies selling topical finasteride for hair loss, only Almirall (Spain) has gone through the entire three stage clinical trial process. The expenses to go through three trials for a topical hair loss product is generally not justifiable to investors. Especially with key ingredients such as finasteride and minoxidil.
Therapy-16
Triple Hair also sells an over-the-counter hair loss product called Therapy-16. For men, it is sold via the brand name Rizn. It is a drug-free once a day formula that is made with natural ingredients. They sell a RIZN Hair Density Spray and RIZN Hair Complex pills. The woman’s Therapy-16 Hair Densifying Spray product goes by the brand name Plenty Natural. It contains Japanese knotweed, melatonin and peasprout extracts.
Interestingly, the company claims that these products reduce Prostaglandin D2 (PGD2) levels, which aid hair growth. I discussed the positive impact of decreasing PGD2 on hair growth in several posts in the past. However, I am skeptical about how big an impact natural products can have on scalp PGD2 levels.
Anyone know the monthly cost for the product through Texas based Pharmacy Solutions? It would be nice to have an approximate cost before going through the provider process in case cost is prohibitive.
I was on Triple Hair’s formula through the Texas-based pharmacy until last spring. The cost (give or take) was about $167 per prescription. But that was last year. The positive was that each time I dealt with that pharmacy, they were very friendly. The negative was I was very disappointed with my results. In fact, after all these years (decades!), I am back to finasteride and minoxidil. Pathetic when you think about it. I plan to get off the finsasteride when Cosmo’s drug gets approved. And that will just be a temporary bridge to Pelage (fingers crossed).
And after Pelage, Absci. With a bit of luck the next 5 years are going to be a significant turning point for this disease.
They finally start Phase 3 trials … 5 years later than planned. Well till 04/2028. What a joke.
https://clinicaltrials.gov/study/NCT07435012
Thanks John, for keeping track of such smaller players.
It is a 24 week trial, so very surprising that they want to take 2 years to complete it.
If hair stem already makes a product with the same ingredients and sells them already..why is triple hair spending money doing trials on this….seems counterproductive.